Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin

Neurosurgery

Volumn 64, Issue 3 SUPPL., 2009, Pages

  Kremer, Paul ^a,c   Mahmoudreza, Fardanesh ^a   Ding, Reinhard ^a   Pritsch, Maria ^a   Zoubaa, Saida ^a   Frei, Eva ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Asklepios Klinik Nord Heidberg   (Germany)

Author keywords

Albumin; Covalent albumin conjugate; Drug targeting; Fluorescence guided brain surgery

Indexed keywords

5 AMINOFLUORESCEIN HUMAN SERUM ALBUMIN CONJUGATE; FLUORESCEIN DERIVATIVE; HUMAN SERUM ALBUMIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALLERGIC REACTION; ARGON LASER; ARTICLE; BLEACHING; BLOOD SAMPLING; BRAIN EDEMA; BRAIN TUMOR; CANCER SURGERY; CLINICAL ARTICLE; CONJUGATE; CONTROLLED STUDY; COVALENT BOND; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LABORATORY; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN MANIFESTATION; TUMOR VOLUME;

ADULT; AGED; BRAIN NEOPLASMS; CELL PROLIFERATION; FEMALE; FLUORESCEINS; GLIOBLASTOMA; GLIOMA; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MEDULLOBLASTOMA; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; OLIGODENDROGLIOMA; PARAFFIN EMBEDDING; SERUM ALBUMIN; TISSUE FIXATION;

EID: 62849095987     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000335787.17029.67     Document Type: Article

References (37)

1. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumour and its influence on regrowth and prognosis. Neurosurgery 34:45-61, 1994.
2. Andersson C, Iresjö BM, Lundholm K: Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J Surg Res 50:156-162, 1991.
3. Behrem S, Zarkovió K, Eskinja N, Jonjió N: Distribution pattern of tenascin-C in glioblastoma: Correlation with angiogenesis and tumor cell proliferation. Pathol Oncol Res 11:229-235, 2005.
4. Boiling C, Graefe T, Lübbing C, Jankevicius F, Uktveris S, Cesas A, Meyer-Moldenhauer WH, Starkmann H, Weigel M, Burk K, Hanauske AR: Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 24:521-527, 2006.
5. Bonsanto MM, Staubert A, Wirtz CR, Tronnier V, Kunze S: Initial experience with an ultrasound-integrated single-RACK neuronavigation system. Acta Neurochir (Wien) 143:1127-1132, 2001.
6. Hammoud MA, Ligon BL, elSouki R, Shi WM, Schomer DF, Sawaya R: Use of intraoperative ultrasound for localizing tumors and determining the extent of resection: A comparative study with magnetic resonance imaging. J Neurosurg 84:737-741, 1996.
7. Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W: Phase I trial of a methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 5:753-759, 1999.
8. Kremer P, Tronnier V, Steiner HH, Metzner R, Ebinger F, Rating D, Hartmann M, Seitz A, Unterberg A, Wirtz CR: Intraoperative MRI for interventional neurosurgical procedures and tumor resection control in children. Childs Nerv Syst 22:674-678, 2006.
9. Kremer P, Hartung G, Bauder-Wüst U, Schrenk HH, Wunder A, Heckl S, Zillmann U, Sinn H: Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats. Anticancer Drugs 13:615-623, 2002.
10. Kremer P, Wunder A, Sinn H, Haase T, Rheinwald M, Zillmann U, Albert FK, Kunze S: Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: Experimental and preliminary clinical results. Neurol Res 22:481-489, 2000.
11. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001.
12. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Kratz F, Walker UA: The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 120:927-934, 2007.
13. Moan J, Ma L, Iani V, Juzeniene A: Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after application of 5-aminolevulinic acid methyl ester. J Invest Dermatol 125:1039-1044, 2005.
14. Moore GE, Peyton WT, French LA, Walker WW: The clinical use of fluorescein in neurosurgery. The localization of brain tumors. J Neurosurg 5:392-398, 1948.
15. Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R: Intraoperative visualization for resection of gliomas: The role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res 28:482-487, 2006.
16. Pepe MS: The statistical evaluation of Medical Tests for Classification and Prediction. Oxford, Oxford University Press, 2003, pp 58-65.
17. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA Jr, Attie AD: A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 212:791-800, 1983.
18. Pommerenke EW, Sinn H, Volm M: Cirumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin. Eur J Cancer 31A:283-284, 1995.
19. Sarkar C, Karak AK, Nath N, Sharma MC, Mahapatra AK, Chattopadhyay P, Sinha S: Apoptosis and proliferation: Correlation with p53 in astrocytic tumours. J Neurooncol 73:93-100, 2005.
20. Schilling U, Friedrich EA, Sinn H, Schrenk HH, Clorius JH, Maier-Borst W: Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part II. In vivo studies. Int J Rad Appl Instrum B 19:685-695, 1992.
21. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier-Borst W: Design of compounds having an enhanced tumor uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum B 17:819-827, 1990.
22. Smith PJ, Hadgu A: Sensitivity and specificity for correlated observations. Stat Med 11:1503-1509, 1992.
23. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL: Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26:77-100, 1997.
24. Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H: Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer Drugs 10:405-411, 1999.
25. Stehle G, Sinn H, Wunder A, Schrenk HH, Schutt S, Maier-Borst W, Heene DL: The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 8:677-685, 1997.
26. Stehle G, Wunder A, Sinn H, Schrenk HH, Schutt S, Frei E, Hartung G, Maier-Borst W, Heene DL: Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs 8:835-844, 1997.
27. Stummer W, Pichlmeier U, Meinel T, Wiestier OD, Zanella F, Reulen HJ; ALA-Glioma Study Group: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401, 2006.
28. Thorpe SR, Baynes JW, Chroneos ZC: The design and application of residualizing labels for studies of protein catabolism. FASEB J 7:399-405, 1993.
29. Tronnier VM, Wirtz CR, Knauth M, Lenz G, Pastyr O, Bonsanto MM, Albert FK, Kuth R, Staubert A, Schlegel W, Sartor K, Kunze S: Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery 40:891-902, 1997.
30. Vis AN, van der Gaast A, van Rhijn BW, Catsburg TK, Schmidt C, Mickisch GH: A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 49:342-345, 2002.
31. Wessels JM, Sroka R, Heil P, Seidlitz HK: Photodegradation of protoporphyrin-dimethylester in solution and in organized environments. Int J Radiat Biol 64:475-484, 1993.
32. Wirtz CR, Knauth M, Staubert A, Bonsanto MM, Sartor K, Kunze S, Tronnier VM: Clinical evaluation and follow-up results for intraoperarive magnetic resonance imaging in neurosurgery. Neurosurgery 46:1112-1122, 2000.
33. Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL: Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 89:52-59, 1998.
34. Woydt M, Krone A, Becker G, Schmidt K, Roggendorf W, Roosen K: Correlation of intra-operative ultrasound with histopathologic findings after tumour resection in supratentorial gliomas. A method to improve gross total tumour resection. Acta Neurochir (Wien) 138:1391-1398, 1996.
35. Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H: Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 76:884-890, 1998.
36. Wunder A, Stehle G, Sinn H, Schrenk HH, Hoff-Biederbeck D, Bader F, Friedrich EA, Peschke P, Maier-Borst W, Heene DL: Enhanced albumin uptake by rat tumors. Int J Oncol 11:497-507, 1997.
37. Zeger SL, Liang KY, Albert PS: Models for longitudinal data: A generalized estimating equation approach. Biometrics 44:1049-1060, 1988.